Next generation CAR-T cells are coming to the clinic in 2024
It's beginning to look a lot like Christmas...
What to watch for in emerging CAR-T cell therapy approaches and how they may give antibodies a run for their money
10 IO topics to watch out for at ASH23
In our latest Preview from the American Society of Hematology, we’re using the dragon’s…
How a competitive landscape can change drastically over a short time
W2W4 at SITC23 - 10 emerging areas to pay attention to in IO
Eight key areas to watch out for at SITC 2023!
As we head into the long August Bank Holiday and Labor Day celebrations, I wanted to offer some…
Progress report on a varied China based CAR-T cell program
From autologous to gene edited CARs and much in between - W2W4 on 14 next gen products
Opportunities and challenges abund for several next-gen CAR-T cell therapies
Next generation CAR-T cell therapies for solid tumours
What's new on the CAR-T cell therapy front?
Improving cell therapy performance with a multitude of innovative strategies
Key developments which could kickstart a renaissance for CAR-T cells in solid tumours
A look at some new developments in CAR-T cell therapy for gliomas
How base editing can transform the development of next gen CAR-T cell therapies
What can we learn from a raft of early cell therapy companies with novel or intriguing approaches?
Highlights from Day 1 CART22 Part 2
Highlights from Day 1 of CART22, part 1
Overcoming the limitations associated with CAR-T performance and lack of persistence
A dozen early stage biotechs in the RAS/RAF pathway to watch out for
Novel approaches to fine tuning CAR-T cell therapies are hitting the clinic
SITC 2021 Preview
Commentary on engineered NK cells, including CAR-NK and memory-like NK cells
Rock around the CAR-T cell clock to learn what to watch out for at ASH20!
Using CRISPR screens to find new targets for enhancing T cell fitness
Can we influence T cell fitness and performance by manipulating metabolic processes?
If we were to tackle CAR T cell therapy design differently, how would we go about doing it?
The ups and downs of CAR-T cell therapy development continues apace
Can we make NK cells work harder with gene editing? It looks as though this will be a feasible strategy to pursue...
Some hidden gems and under the radar abstracts that may appeal to the off-Broadway crowd at ASH19
Commentary on some up and coming biotechs in the oncology space
A look at path to market strategies open to a small biotech in the CAR-T cell space
A look at what's happening with Cellectis and their clinical trial program with CD19 and CD123 CARs.
What does the future hold for Cellectis and allogeneic "off the shelf" CAR T cell therapy?
Gene editing looks set to become entrenched in allogeneic CAR T cell development, so what's new?
Insight from BMT Tandem 2017 meeting into latest Cell Therapy data
Commentary on Wednesday at JPM17 in San Francisco
A look at the emerging trends we can expect in 2017 for cancer research
Initial impressions of abstracts for ASH16 in San Diego
How will glycomics impact cancer research? Some interesting new developments are emerging in this field
Collaborations in the adoptive cell therapy space have now branched out from autologous to allogeneic products. What's the skinny?
Gene editing is coming to the US CAR T cell space - what's happening and what will the impact be?
Part 2 of ASH 2015 interview with Prof Waseem Qasim (GOSH) on the first in man gene edited allogeneic CAR T cell therapy.
Part 1 of an interview with Prof Waseem Qasim.
Do you need to incorporate a suicide suicide switch into CAR T cells that allows you to turn off the response, force the T cells to self-destruct?
Dr Krishna Komanduri discusses some of the best abstracts at the 2015 BMT Tandem meeting in San Diego.
Yumanity seeks to transform drug discovery for neurodegenerative diseases caused by protein misfolding.
Transcription factors are becoming a new buzzword in cancer research - why are they important for drug development?
Bluebird bio is an emerging biotech company with a novel lentiglobin gene therapy in development that could revolutionize the treatment of beta-thalassemia and sickle cell disease.
There is no available cure for patients with beta-thalassemia or sickle cell disease, but new developments are very encouraging
What makes the Cellectis Chimeric Antigen Receptor CAR-T cell therapy different and what are the milestones expected in 2015?
Cellectis is a Paris based biotechnology company with a “blue ocean” strategy that, if successful, could revolutionize cancer immunotherapy.
Restoration of hearing in mice by gene transfer is a major breakthrough